Comparing Long-Term Outcomes Across Varying Grades of Knee Osteoarthritis – A Real-World Cohort Study
November 1, 2022
Comparing Long-Term Outcomes Across Varying Grades of Knee Osteoarthritis – A Real-World Cohort Study
Millions of patients each year are affected by knee osteoarthritis. The severity of this condition is often categorized using the Kellgren-Lawrence (KL) scale, which uses the numbers 0 through 4 to represent the absence or varying grades of symptom presentation. Patients with long-term and/or severe symptoms are often indicated for surgery, while patients with minimal symptoms can employ simpler tools, such as NSAIDS. But what about the many patients who are stuck in the middle, too early for surgery and far past the role of over-the-counter medication?
This is known as the treatment gap, and Drs. Guillermo Alvarez Rey, M.D. and Carlos Ferrer Señorans, M.D. of AMS Centro Médico in Málaga, Spain, are intent on shedding light on this prevalent question. Using RegenMed’s inCytes™ technology, and deploying their own non-surgical treatment methods, they have captured and correlated their own patients’ KL grade to long-term outcomes. Early and average results so far show:
- Patients with a lower KL grade (0-1) can expect significant improvement, almost to a perfect score.
- Patients with mild to moderate OA can still expect improvement, up to around 30% on average after 12 months.
- Even more interestingly, patient suffering from severe OA (KL 4) can experience some slight improvement, though early results do show a faster return to baseline.
These data play an invaluable role in helping set patient expectations, informing Dr. Alvarez and Señorans on more personalized patient treatment decisions, and may well help inform standards in the Treatment Gap space in the future.
Comparing Long-Term Outcomes Across Varying Grades of Knee Osteoarthritis – A Real-World Cohort Study
November 1, 2022
Millions of patients each year are affected by knee osteoarthritis. The severity of this condition is often categorized using the Kellgren-Lawrence (KL) scale, which uses the numbers 0 through 4 to represent the absence or varying grades of symptom presentation. Patients with long-term and/or severe symptoms are often indicated for surgery, while patients with minimal symptoms can employ simpler tools, such as NSAIDS. But what about the many patients who are stuck in the middle, too early for surgery and far past the role of over-the-counter medication?
This is known as the treatment gap, and Drs. Guillermo Alvarez Rey, M.D. and Carlos Ferrer Señorans, M.D. of AMS Centro Médico in Málaga, Spain, are intent on shedding light on this prevalent question. Using RegenMed’s inCytes™ technology, and deploying their own non-surgical treatment methods, they have captured and correlated their own patients’ KL grade to long-term outcomes. Early and average results so far show:
- Patients with a lower KL grade (0-1) can expect significant improvement, almost to a perfect score.
- Patients with mild to moderate OA can still expect improvement, up to around 30% on average after 12 months.
- Even more interestingly, patient suffering from severe OA (KL 4) can experience some slight improvement, though early results do show a faster return to baseline.
These data play an invaluable role in helping set patient expectations, informing Dr. Alvarez and Señorans on more personalized patient treatment decisions, and may well help inform standards in the Treatment Gap space in the future.
